Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
about
Tranexamic acid for reducing mortality in emergency and urgent surgeryTransfusion thresholds and other strategies for guiding allogeneic red blood cell transfusionAntifibrinolytic therapy to reduce haemoptysis from any causeAntifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disordersAnti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disordersAntifibrinolytic drugs for acute traumatic injury.Methods to decrease blood loss and transfusion requirements for liver transplantationDesmopressin for minimising perioperative allogeneic blood transfusionCoagulopathy and transfusion therapy in pediatric liver transplantationEpsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trialsIs tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trialsBleeding related to disturbed fibrinolysisEfficacy and safety of using antifibrinolytic agents in spine surgery: a meta-analysisHemostatic abnormalities in critically ill patients.Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series.Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.Searching ClinicalTrials.gov and the International Clinical Trials Registry Platform to inform systematic reviews: what are the optimal search approaches?Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid -- a meta-analysis of randomised and observational trials of over 30.000 patientsHALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial.Report from AmSECT's International Consortium for Evidence- Based Perfusion Consensus Statement: Minimal Criteria for Reporting Cardiopulmonary Bypass-Related Contributions to Red Blood Cell Transfusions Associated With Adult Cardiac Surgery.Continuous Postoperative Pericardial Flushing: A Pilot Study on Safety, Feasibility, and Effect on Blood Loss.Patterns of use of hemostatic agents in patients undergoing major surgery.Randomized clinical trial of topical tranexamic acid after reduction mammoplasty.Use of a Thrombin Fibrin Sealant in Reducing Blood Loss in Revision Hip Arthroplasty.The Value of Tranexamic Acid in Reducing Blood Loss following Hip Reconstruction in Children with Cerebral Palsy.A comparison of high-dose and low-dose tranexamic acid antifibrinolytic protocols for primary coronary artery bypass surgeryRecurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy useMajor liver resection, systemic fibrinolytic activity, and the impact of tranexamic acid.Role of Prophylactic Tranexamic Acid in Reducing Blood Loss during Elective Caesarean Section: A Randomized Controlled Study.Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.Perioperative blood management.Patient blood management to reduce surgical risk.Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis.Desmopressin use for minimising perioperative blood transfusion.Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery.Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis.Antifibrinolytics.Intraoperative care for aortic surgery using circulatory arrest.Blood transfusion and hemostatic agents used during radical cystectomy
P2860
Q24197621-1046A591-B3D8-495A-9C42-091F528977ADQ24200170-94D167CF-A328-4EAC-99D7-2EEF9B509C0DQ24200405-C3BB06CB-1545-4134-A478-338FB98D822BQ24201018-D40153F5-A371-42A9-90C8-DECB91D4E70FQ24201514-870984AC-7D27-4124-AEEA-8A49DF9668CFQ24202390-93737232-6918-469F-A2FA-2C158179D798Q24234278-462C1DD9-9290-41F2-8D13-7F19AE941E3AQ24247402-FEAD039F-04C3-41E5-A6D0-B16BF037A285Q26766108-1BF65249-9735-4A19-BF63-0AFF0EA6A531Q26785349-6512944E-0E51-4B4B-9D4D-F516A44D215AQ26859650-74654C04-9DAA-4E79-B9F8-C11608A794F9Q28070127-9C5A14BE-EF51-467A-A4B1-9432ED38AACCQ28535382-0BE717E0-E336-4D02-ACC0-77A4BAA39186Q33419474-93EBE960-6265-4C76-989E-F0A665755DB9Q33420118-E4B43AB7-ED15-43E0-8D3C-14150A884CDEQ33676496-5F6875A6-0B4F-4FD2-A7F3-762829ED5C02Q33825252-A6C92077-027B-4E05-869F-66637C00974FQ34618556-23215618-D508-4A31-AF90-A7CA4929A8A9Q34620403-DCF8FBC0-CE13-4764-B79D-9D63EE075C3DQ36019367-08031E1F-A0FB-4A70-8E5B-E71252DE4564Q36105422-D74FD104-F2BA-4D05-9469-93672108948BQ36137393-B8B20635-560F-4C19-94D8-EC01B70BB24CQ36143953-D4E69331-BA36-4511-B41B-C01BCDB7D8BFQ36282644-01CE4C6B-8CAB-4725-9C92-34B7E70392B5Q36333184-0874CB4F-78F8-4F2B-B8DA-6E9D8146BF7AQ36675811-02E1D966-8363-45A6-848C-539C60D6C761Q36800361-AB3DF940-F563-4A4F-99C6-E3F1DBAFA432Q37484574-1F8CFB93-529C-41EB-84CD-C25438D4D4F8Q37630120-23BD38DC-302C-471A-B4F7-E3845165D295Q38042573-5694EC60-0796-456B-A0DB-219606C2E89BQ38298635-734304DE-5DCC-4ACE-8DF9-0E28816AFD9FQ38575053-BB91B9D1-FA10-4C8D-AC99-29B27EC3EDFBQ38653755-5881BC09-9E68-44E5-B672-88303B4AC6E2Q38687047-E36AD6B7-530E-4F82-A18D-6AC0B3CC0C0CQ38928171-72EC5EEB-8208-494D-9AE9-AE6A0BA174CFQ38937171-8B16BB2A-3D99-43FE-8571-023F059B8425Q38965043-A3F4D760-60D3-4EBD-9619-2B5E6E551F8EQ39208270-2C1D72EE-2F98-4233-91E8-73B98915CDA6Q39374733-EB06479D-DBE1-46F9-8FBB-75F37EF988A7Q41255396-8D866427-C411-43E1-A2B3-77E80657B2FE
P2860
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@ast
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en-gb
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@nl
type
label
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@ast
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en-gb
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@nl
prefLabel
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@ast
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en-gb
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@nl
P2093
P1476
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
@en
P2093
Annette J Moxey
Barrie J Stokes
David A Henry
Dean A Fergusson
Dianne O'Connell
Paul A Carless
P356
10.1002/14651858.CD001886.PUB3
P577
2011-01-19T00:00:00Z